Prevalence of cranial autonomic parasympathetic symptoms in chronic migraine: Usefulness of a new scale

• Published in: Cephalalgia 2016-04, Vol.36 (4), p.346-350
• Main Authors: Riesco, Nuria, Pérez-Alvarez, Angel I, Verano, Laura, García-Cabo, Carmen, Martínez-Ramos, Juana, Sánchez-Lozano, Pablo, Cernuda-Morollón, Eva, Pascual, Julio
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Autonomic Nervous System Diseases - epidemiology; Autonomic Nervous System Diseases - etiology; Female; Humans; Male; Middle Aged; Migraine Disorders - complications; Prevalence; Severity of Illness Index; Young Adult
• ISSN: 0333-1024; 1468-2982
• DOI: 10.1177/0333102415593087

Background Cranial autonomic symptoms (CAS) seem to appear in around half of migraine patients. Objective Our aim was to analyse the prevalence and profile of CAS, mainly of cranial autonomic parasympathetic symptoms (CAPS), in a series of patients with chronic migraine (CM) according the new criteria for autonomic symptoms in the current IHS classification. Patients and methods We recruited consecutive CM patients attending our headache clinic. Five CPAS were surveyed: lacrimation, conjunctival injection, eyelid oedema, ear fullness and nasal congestion. They were graded as 0 (absent), 1 (present and mild) and 2 (present and conspicuous); therefore the score in this CAPS scale ranges from 0 to 10 points. As a cranial autonomic sympathetic symptom (CSAS), we also asked about the presence of ptosis. Results We interviewed 100 CM patients. Their mean age was 45 years (18–63 years); 93 were females. Eighteen had no CAPS, while 82 reported at least one CAPS. There were only six patients with scores higher than 5, the mean and median CAPS being 2.1 and 2, respectively. Prevalence of CAPS was lacrimation (49%), conjunctival injection (44%), eyelid oedema (39%), ear fullness (30%) and nasal congestion (20%). Ptosis was reported by 42. Conclusion These results, by using for the first time an easy quantitative scale, confirm that (mild) CAPS are not the exception but the rule in CM patients. The score in this CAPS scale could be of help as a further endpoint in clinical trials or to be correlated with potential biomarkers of parasympathetic activation in primary headaches.